Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00302237 · ClinicalTrials.gov registry record
CAPTURE 2 Post-Marketing Registry
A clinical trial of Carotid Artery Disease, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 6,426
- Enrollment target
- 1
- Study location
NCT00302237 is a study of Carotid Artery Disease that has completed, run by Abbott Medical Devices. The registered enrollment target is 6,426 participants, below the 12,448-participant average among 5 other Carotid Artery Disease trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00302237, a study of Carotid Artery Disease, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 6,426 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of the registry are: 1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
Conditions Studied
Interventions
- DEVICE RX ACCULINK, RX ACCUNET Embolic Protection System
Study Locations (1)
California
- Abbott Vascular - Santa Clara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,426 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00302237
The ClinicalTrials.gov registry entry for NCT00302237 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6,426 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,448-participant average among 5 other Carotid Artery Disease trials with a reported enrollment target (48% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carotid Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which RX ACCULINK, RX ACCUNET Embolic Protection System is the first listed.
NCT00302237 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00302237 about?
NCT00302237 is a clinical study titled "CAPTURE 2 Post-Marketing Registry". The purposes of the registry are: 1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the...
What is the current status of trial NCT00302237?
This trial is currently completed. The enrollment target is 6,426 participants. The study started on 2006-03. Estimated completion is 2010-05.
What conditions does trial NCT00302237 study?
This clinical trial studies the following conditions: Carotid Artery Disease.
What interventions are being tested in trial NCT00302237?
The interventions under investigation include: RX ACCULINK, RX ACCUNET Embolic Protection System (DEVICE).
Who is sponsoring clinical trial NCT00302237?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00302237 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carotid Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SVS VQI TransCarotid Revascularization Surveillance Project
RECRUITING
-
The Gore SCAFFOLD Clinical Study
COMPLETED · NA
-
Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study
COMPLETED · NA
-
Assessment Of Vascular Health After Niacin Therapy (AVANT)
COMPLETED · NA
-
Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.